Will warfarin ever be replaced?

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 15, Issue 3, 2010, Pages 210-219

  Ruff, Christian T ^a   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

novel anticoagulant; thromboembolism; vitamin K antagonist; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; DABIGATRAN; DU 176B; ENOXAPARIN; PLACEBO; RIVAROXABAN; THIENOPYRIDINE DERIVATIVE; WARFARIN;

ACUTE CORONARY SYNDROME; BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DYSPEPSIA; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SIDE EFFECT; STROKE; VENOUS THROMBOEMBOLISM;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; STROKE; THROMBIN; THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 77956849181     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248410366448     Document Type: Review

References (59)

1. Schofield FW Damaged sweet clover; the cause of a new disease in cattle stimulating haemorrhagic septicemia and black leg. J Am Vet Med Ass. 1924 ; 64: 553-556.
2. Roderick LM A problem in the coagulation of the blood: "sweet clover disease of cattle.". Am J Physiol. 1931 ; 96: 413-425.
3. Stahmann MA, Huebner CF, Link KP Studies on the Hemorrhagic Sweet Clover Disease. Journal of Biological Chemistry. 1941 ; 138: 513-527.
4. Link KP The discovery of dicumarol and its sequels. Circulation. 1959 ; 19 (1). 97-107.
5. Fasco MJ, Hildebrandt EF, Suttie JW Evidence that warfarin anticoagulant action involves two distinct reductase activities. J Biol Chem. 1982 ; 257 (19). 11210-11212.
6. Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 ; 126 (3 suppl). 204S - 233S. (Pubitemid 39297955)
7. Turpie AG New oral anticoagulants in atrial fibrillation. Eur Heart J. 2008 ; 29 (2). 155-165.
8. Aithal GP, Day CP, Kesteven PJ, Daly AK Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999 ; 353 (9154). 717-719.
9. DAndrea G., DAmbrosio RL, Di Perna P., et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005 ; 105 (2). 645-649.
10. Marin F., Gonzalez-Conejero R., Capranzano P., Bass TA, Roldan V., Angiolillo DJ Pharmacogenetics in cardiovascular antithrombotic therapy. J Am Coll Cardiol. 2009 ; 54 (12). 1041-1057.
11. Jones M., McEwan P., Morgan CL, Peters JR, Goodfellow J., Currie CJ Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart. 2005 ; 91 (4). 472-477.
12. Weitz JI, Bates SM New anticoagulants. J Thromb Haemost. 2005 ; 3 (8). 1843-1853.
13. Eriksson BI, Quinlan DJ, Weitz JI Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet. 2009 ; 48 (1). 1-22.
14. Mann KG, Brummel K., Butenas S. What is all that thrombin for? J Thromb Haemost. 2003 ; 1 (7). 1504-1514.
15. Gustafsson D., Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res. 2003 ; 109 (suppl 1). S9-15.
16. Stangier J., Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005 ; 45 (5). 555-563.
17. Stangier J., Rathgen K., Stahle H., Gansser D., Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007 ; 64 (3). 292-303.
18. Stangier J., Stahle H., Rathgen K., Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008 ; 47 (1). 47-59. (Pubitemid 350260888)
19. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008 ; 47 (5). 285-295. (Pubitemid 351508116)
20. European Medicines Agency (EMEA). European public assessment report: Pradaxa [online]. http://www.emea.europa.eu/humandocs/PDFs/EPAR/pradaxa/H-829- PI-en.pdf. Accessed January 15, 2010.
21. Eriksson BI, Dahl OE, Rosencher N., et al. RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007 ; 370 (9591). 949-956.
22. Eriksson BI, Dahl OE, Rosencher N., et al. RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007 ; 5 (11). 2178-2185.
23. RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 ; 24 (1). 1-9.
24. Schulman S., Kearon C., Kakkar AK, et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009 ; 361 (24). 2342-2352.
25. Oldegren J. 2009 Late-Breaking Clinical Trial/Science Abstracts From the AHA Scientific Sessions 2009. Circulation. 2009 ; 120 (21). 2152-2161.
26. Connolly SJ, Ezekowitz MD, Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 ; 361 (12). 1139-1151.
27. Kubitza D., Becka M., Wensing G., Voith B., Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005 ; 61 (12). 873-880.
28. Kubitza D., Becka M., Voith B., Zuehlsdorf M., Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005 ; 78 (4). 412-421.
29. Kubitza D., Becka M., Roth A., Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin. 2008 ; 24 (10). 2757-2765.
30. Gross PL, Weitz JI New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol. 2008 ; 28 (3). 380-386.
31. Kubitza D., Becka M., Zuehlsdorf M., Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006 ; 46 (5). 549-558.
32. Kubitza D., Becka M., Mueck W., Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct factor Xa inhibitor-are not affected by aspirin. J Clin Pharmacol. 2006 ; 46 (9). 981-990.
33. kubitza D., Becka M., Zuelsdorf M., Mueck W. No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin. (Abstract 11). J Clin Pharmacol. 2006 ; 46: 702.
34. Eriksson BI, Borris LC, Friedman RJ, et al. RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008 ; 358 (26). 2765-2775.
35. Kakkar AK, Brenner B., Dahl OE, et al. RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008 ; 372 (9632). 31-39.
36. Lassen MR, Ageno W., Borris LC, et al. RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008 ; 358 (26). 2776-2786.
37. Turpie AGG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009 ; 373 (9676). 1673-1679.
38. FDA Cardiovascular and Renal Drugs Advisory Committee Meeting, March 19, 2009. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ UCM143660.pdf. Accessed January 15, 2010.
39. Garcia D., Libby E., Crowther MA The new oral anticoagulants. Blood. 2010 ; 115 (1). 15-20.
40. Buller HR, Lensing AWA, Prins MH, et al, on behalf of the Einstein-DVT Dose-Ranging Study investigators. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008 ; 112 (6). 2242-2247.
41. Mega JL, Braunwald E., Mohanavelu S., et al. ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009 ; 374 (9683). 29-38.
42. The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators. Rivaroxaban-oncedaily, oral, direct factor xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: Rationale and design of the ROCKET AF study. Am Heart J. 2010 ; 159: 340, 347.el.
43. Gage BF, Waterman AD, Shannon W., Boechler M., Rich MW, Radford MJ Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001 ; 285 (22). 2864-2870.
44. Ogata K., Mendell-Harary J., Tachibana M., et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010 [Epub ahead of print].
45. Mendell J., Noveck R., Rubets I., Luo R., Shi M., Salazar D. The factor Xa inhibitor edoxaban (DU-176b) is safe in healthy subjects 24 hours post warfarin treatment: a randomized, double-blind study [abstracts]. J Thromb Haemost. 2009 ; 7 (suppl 2) 1636.
46. Mendell J., Rohatagi R., Rombout F., et al. The oral factor xa inhibitor edoxaban (DU-176b): population pharmacokinetic and pharmacodynamic models of coagulation biomarkers, efficacy and safety [abstract]. Clin Pharmacol Ther. 2009 ; 85 (S1). S36.
47. Giugliano RP, Rohatagi R., Kastrissios H., et al. The relationship between oral factor xa (FXa) inhibitor DU-176b pharmacokinetics (PK) and the probability of bleeding events (BE) in patients with atrial fibrillation (AF) [abstract]. J Thromb Haemost. 2009 ; 7: 200.
48. Weitz JI, Connolly SJ, Kunitada S., Jin J., Patel I. Randomized, parallel group, multicenter, multinational study evaluating safety of DU-176b compared with warfarin in subjects with non-valvular atrial fibrillation [abstract]. Blood. 2008 ; 112 (11). 33.
49. Pocock SJ The pros and cons of noninferiority trials. Fundam Clin Pharmacol. 2003 ; 17 (4). 483-490.
50. Gao P., Ware JH Assessing non-inferiority: a combination approach. Stat Med. 2008 ; 27 (3). 392-406.
51. Kaul S., Diamond GA, Weintraub WS Trials and tribulations of non-inferiority: the ximelagatran experience. J Am Coll Cardiol. 2005 ; 46 (11). 1986-1995.
52. Raghavan N., Frost CE, Yu Z., et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009 ; 37 (1). 74-81.
53. Weitz JI Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost. 2006 ; 96 (3). 274-284.
54. Lassen MR, Raskob GE, Gallus A., Pineo G., Chen D., Portman RJ Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009 ; 361 (6). 594-604.
55. Lassen MR, Gallus AS, Pineo GF, Raskob GE The ADVANCE-2 Study: a randomized double-blind trial comparing apixaban with enoxaparin for thromboprophylaxis after total knee replacement ISTH Late Breaking Clinical Trials 2009 (LB-MO-004). J Thromb Haemost. 2009 ; 7 (suppl 2). 1203-1204.
56. Investigators ASCa. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome. Results of the apixaban for prevention of acute ischemic and safety events (APPRAISE) trial. Circulation. 2009 ; 119 (22). 2877-2885.
57. Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: Design and rationale. Am Heart J. 2010 ; 159: 331-339.
58. Albers GW, Diener HC, Frison L., et al; SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005 ; 293 (6). 690-698.
59. Olsson SB ;. Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003 ; 362 (9397). 1691-1698.